{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:41Z","timestamp":1759017881093,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clinthera.2019.04.029","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T18:01:15Z","timestamp":1558634475000},"page":"1057-1065.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients a\u00a0US Observational Cohort"],"prefix":"10.1016","volume":"41","author":[{"given":"Evo","family":"Alemao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine K.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Shadick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.04.029_bib1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.029_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/ar395","article-title":"Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value","volume":"4","author":"van Boekel","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.clinthera.2019.04.029_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.7326\/0003-4819-152-7-201004060-00010","article-title":"Systematic review: accuracy of anti\u2013citrullinated peptide antibodies for diagnosing rheumatoid arthritis","volume":"152","author":"Whiting","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.04.029_bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11926-011-0193-7","article-title":"Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance","volume":"13","author":"Demoruelle","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clinthera.2019.04.029_bib5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.029_bib6","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/ard.2004.033571","article-title":"Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression","volume":"64","author":"Ronnelid","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.029_bib7","doi-asserted-by":"crossref","first-page":"R949","DOI":"10.1186\/ar1767","article-title":"Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis","volume":"7","author":"van der Helm-van Mil","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2019.04.029_bib8","first-page":"222","article-title":"Alveolar bone loss is associated with circulating anti-citrullinated protein antibody (ACPA) in patients with rheumatoid arthritis","volume":"86","author":"Gonzalez","year":"2014","journal-title":"J\u00a0Peridontol"},{"key":"10.1016\/j.clinthera.2019.04.029_bib9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12325-017-0657-x","article-title":"Association of low bone mineral density with anti-citrullinated protein antibody positivity and disease activity in established rheumatoid arthritis: findings from a US observational cohort","volume":"35","author":"Ahmad","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2019.04.029_bib10","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.30537","article-title":"Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis","volume":"63","author":"van de Stadt","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.029_bib11","first-page":"31","article-title":"Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis","volume":"6","author":"Hasan","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.clinthera.2019.04.029_bib12","doi-asserted-by":"crossref","first-page":"e000564","DOI":"10.1136\/rmdopen-2017-000564","article-title":"Conversion to seronegative status after abatacept treatment in patients ith early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study","volume":"4","author":"Jansen","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.clinthera.2019.04.029_bib13","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1136\/annrheumdis-2018-213823","article-title":"In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission","volume":"77","author":"de Moel","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.029_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/annrheumdis-2012-202297","article-title":"Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis","volume":"72","author":"Bohler","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.029_bib15","first-page":"4","article-title":"The economic burden of ACPA-positive status among patients with rheumatoid arthritis","volume":"24","author":"Shafrin","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2019.04.029_bib16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00296-017-3739-9","article-title":"Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada","volume":"37","author":"Weijers","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2019.04.029_bib17","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/rheumatology\/kew261","article-title":"Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data","volume":"55","author":"Pratt","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2019.04.029_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3899\/jrheum.121521","article-title":"Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry","volume":"41","author":"Bykerk","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.029_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/rheumatology\/keq263","article-title":"Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study","volume":"50","author":"Iannaccone","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2019.04.029_bib20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/acr.21940","article-title":"Factors associated with attrition in a longitudinal rheumatoid arthritis registry","volume":"65","author":"Iannaccone","year":"2013","journal-title":"Arthritis Care Res (hoboken)"},{"key":"10.1016\/j.clinthera.2019.04.029_bib21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11926-015-0501-8","article-title":"Patient reported outcomes in rheumatoid arthritis clinical trials","volume":"17","author":"Orbai","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clinthera.2019.04.029_bib22","article-title":"Anti-citrullinated peptide antibodies testing rate over time in newly diagnosed RA patients \u2013 data from three administrative claims databases (2007\u20132014) [abstract]","volume":"68","author":"Alemao","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.029_bib23","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1136\/annrheumdis-2014-206623","article-title":"The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis","volume":"74","author":"van Steenbergen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.029_bib24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2016.09.011","article-title":"Effects of DMARDs on citrullinated peptide auto-antibody levels in RA patients\u2014a longitudinal analysis","volume":"46","author":"Wunderlich","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2019.04.029_bib25","first-page":"424","article-title":"Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotype serum levels in patients with rheumatoid arthritis following treatment with different biological drugs","volume":"34","author":"Iannone","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.029_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13075-019-1815-0","article-title":"In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response","volume":"21","author":"de Moel","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2019.04.029_bib27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3899\/jrheum.130905","article-title":"Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis","volume":"41","author":"Scarsi","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.029_bib28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.029_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","article-title":"Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study","volume":"75","author":"Haschka","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2019.04.029_bib30","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:07Z","timestamp":1758963007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819301961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0149291819301961"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.029","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients a\u00a0US Observational Cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}